Scarica l'app Stockscreener
103.16
0.60%
-0.62
Dopo l'orario di chiusura:
103.12
-0.04
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$103.78
Aprire:
$104.23
Volume 24 ore:
7.92M
Relative Volume:
1.07
Capitalizzazione di mercato:
$152.62B
Reddito:
$17.55B
Utile/perdita netta:
$2.03B
Rapporto P/E:
75.30
EPS:
1.37
Flusso di cassa netto:
$2.72B
1 W Prestazione:
-0.31%
1M Prestazione:
+1.84%
6M Prestazione:
+2.84%
1 anno Prestazione:
+31.80%
Intervallo 1D:
$103.16
$104.56
Intervallo di 1 settimana:
$102.26
$105.40
Portata 52W:
$71.88
$107.53
Boston Scientific Corp Stock (BSX) Company Profile
Nome
Boston Scientific Corp
Settore
Industria
Telefono
508-683-4000
Indirizzo
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Confronta BSX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Leerink Partners | Outperform |
| 2025-04-16 | Aggiornamento | Needham | Hold → Buy |
| 2025-01-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Downgrade | Needham | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-20 | Ripresa | Citigroup | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-06 | Iniziato | Wolfe Research | Outperform |
| 2022-05-27 | Aggiornamento | Needham | Hold → Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-26 | Downgrade | Needham | Buy → Hold |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-17 | Iniziato | Truist | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Buy |
| 2019-12-30 | Reiterato | Cowen | Outperform |
| 2019-12-19 | Downgrade | Needham | Strong Buy → Buy |
| 2019-09-05 | Ripresa | JP Morgan | Overweight |
| 2019-09-03 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-10-02 | Reiterato | Morgan Stanley | Overweight |
| 2018-09-07 | Reiterato | Needham | Strong Buy |
| 2018-09-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-07-06 | Reiterato | Needham | Strong Buy |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-04-26 | Reiterato | Needham | Strong Buy |
Mostra tutto
Boston Scientific Corp Borsa (BSX) Ultime notizie
Boston Scientific (BSX) Anticipates Robust Q2 Earnings Growth - GuruFocus
Is Boston Scientific Corporation a good long term investmentHigh-yield portfolio picks - jammulinksnews.com
FDA expands Boston Sci’s Watchman label to post-ablation - BioWorld MedTech
Raymond James maintains Strong Buy on Boston Scientific stock - Investing.com
Boston Scientific Watchman wins FDA expansion for post-ablation patients - MassDevice
Boston Scientific stock set to beat Q2 estimates, says TD Cowen - Investing.com
Boston Scientific: Strong Growth Potential and Positive Outlook Justify Buy Rating - TipRanks
What analysts say about Boston Scientific Corporation stockBreakthrough stock performance - printweek.in
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS - Yahoo Finance
Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System - MSN
Boston Scientific’s Innovation Drive Keeps The Stock Climbing - Finimize
Lobbying Update: $570,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed - Nasdaq
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Is Boston Scientific Corporation (NYSE:BSX) Worth US$103 Based On Its Intrinsic Value? - Yahoo Finance
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings? - MSN
Boston Scientific receives US FDA approval for expanded labelling of Farapulse pulsed field ablation system - Cardiac Rhythm News
Boston Scientific (BSX): A High-Stakes Gamble on Innovation Ahead of Q2 Earnings - AInvest
Why Boston Scientific (BSX) Outpaced the Stock Market Today - Yahoo Finance
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
13 Best Large Cap Stocks to Buy Right Now - Insider Monkey
Boston Scientific’s (BSX) FARAPULSE Approved by FDA for Expanded Labeling - Insider Monkey
Boston Scientific (BSX) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today - Yahoo Finance
North America Ureteroscopes Market Outlook Report 2018-2033 with an Overview of Key CompaniesBoston Scientific, KARL STORZ, Olympus, PENTAX Medical, and Richard Wolf - Yahoo Finance
NICE recommends pulsed field ablation tech for AFib - MassDevice
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Is It Worth Adding Boston Scientific Stock To Your Portfolio Now? - Barchart.com
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now? - Yahoo Finance
Boston Scientific (BSX) Receives a Buy from Citi - The Globe and Mail
Boston Scientific (BSX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Boston Scientific Gets FDA Nod for Expanded Labeling of Pulsed Field Ablation System - Diagnostic and Interventional Cardiology
Boston Scientific gets expanded PFA label for persistent AFib - MedTech Dive
FDA greenlights Boston Sci’s Farapulse for persistent AF - BioWorld MedTech
How Unusual Options Standout Boston Scientific (BSX) Is Signaling A Statistical Edge - Barchart.com
Boston Scientific stock rises as TD Cowen reiterates Buy rating - Investing.com
Boston Scientific (NYSE:BSX) Expands FARAPULSE System FDA Approval For Persistent Atrial Fibrillation - Yahoo Finance
Boston Scientific wins expanded FDA nod for Farapulse PFA - MassDevice
Boston Scientific’s PFA system gets FDA approval for persistent AF - Investing.com
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System - Financial Times
What to Expect From Boston Scientific's Next Quarterly Earnings Report - MSN
Boston Scientific Sues Stryker Over Back Pain Treatment Patent - Bloomberg Law News
Feds Subpoena Boston Scientific Over BridgePoint Deal - Law.com
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Boston Scientific Q2 2025 Earnings: CEO and CFO to Present Full Financial Results July 23 - Stock Titan
Boston Scientific stock hits all-time high at 107.2 USD - Investing.com
Boston Scientific (BSX) Gains Momentum Amid Study Pause on Rival Device | BSX Stock News - GuruFocus
Boston Scientific (BSX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
24-Acre Minnetonka Complex Put Up for Sale by Boston Scientific (BSX) - Insider Monkey
February 2026 Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings - Investing.com Canada
Boston Scientific Corp Azioni (BSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):